证券代码：603983 证券简称：丸美生物 公告编号：2025-016 广东丸美生物技术股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.50元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/9 | － | 2025/6/10 | 2025/6/10 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 22 日的2024年年度股东大会审议通过。 本次利润分配以方案实施前的公司总股本401,000,000股为基数，每股派发现 金红利0.50元（含税），共计派发现金红利200,500,000.00元（含税）。 三、 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | - ...

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 86 HKD, based on absolute and relative valuation results [4][14][6]. Core Insights - The company, Shumei Co., Ltd. (2145.HK), is a multi-brand cosmetics group that has shown remarkable growth, particularly through its main brand, KANS, which has become the second-largest domestic beauty brand in terms of online GMV by 2024 [2][23]. - The company has capitalized on the growth of the Douyin platform, leading to a significant increase in revenue and net profit from 2022 to 2024, with projected compound annual growth rates of 59.3% and 130.5%, respectively [2][4]. - The cosmetics industry in China is experiencing both growth and competition, with opportunities in lower-tier markets and niche segments, particularly in color cosmetics and infant care [3][72]. Company Overview - Shumei Co., Ltd. was established in 2004 and went public in 2022, offering a wide range of products including skincare, maternal and infant care, personal care, and makeup [2][23]. - The main brand, KANS, has been a significant contributor to the company's revenue, accounting for 82.3% of total revenue in 2024, with a projected revenue of 55.91 billion CNY [25][23]. Financial Performance - The company achieved a revenue of 67.93 billion CNY in 2024, representing a year-on-year growth of 62.1%, and a net profit of 7.81 billion CNY, up 69.4% from the previous year [4][5]. - The report forecasts net profits for 2025, 2026, and 2027 to be 10.6 billion CNY, 13.8 billion CNY, and 17.4 billion CNY, respectively, with corresponding EPS of 2.65, 3.47, and 4.37 CNY [4][14]. Industry Analysis - The Chinese cosmetics industry is projected to reach a scale of 537.2 billion CNY in 2024, with a slight decline of 2.0% year-on-year, indicating a shift in consumer preference towards cost-effective products [3][72]. - The competitive landscape is characterized by domestic brands leveraging online channels, with Douyin emerging as a key platform for growth [3][72]. Growth Drivers - The main brand KANS is expected to continue its growth trajectory through product innovation and channel diversification, while the emerging brand Yipai is anticipated to achieve triple-digit growth in revenue for 2023 and 2024 [4][10]. - The company is also exploring new brands and product lines, such as the hair care brand Jifang and the makeup brand NAN beauty, to create multiple growth avenues [4][12].

Core Viewpoint - The cosmetics retail sales in China for January to April 2025 showed a year-on-year increase of 4%, underperforming the overall retail market by 0.7 percentage points, but this represents an improvement compared to 2024. The industry is characterized by four key trends: innovation in personal care products, breakthroughs in ingredient technology, rising emotional consumption, and the continuation of affordable consumption [1][3]. Investment Recommendations - The company recommends increasing holdings in the personal care sector, highlighting quality companies that benefit from product innovation and opportunities in Douyin channels, with key recommendations including Ruoyuchen (003010), Dengkang Oral (001328), and Runben Co. [2] - In the beauty sector, structural opportunities are identified, with key recommendations for companies like Jinbo Biological, Juzi Biological, and Marubi Co. that are positioned to benefit from the collagen restructuring trend. Additionally, brands like Maogeping, Shumei Co., Proya (603605), and Shanghai Jahwa (600315) are expected to gain from the overall increase in domestic market share [2]. - Companies expected to bottom out and potentially see a turning point include Lafang Household (603630), Shuiyang Co. (300740), Betaini (300957), Furuida (600223), Huaxi Biological, Fulejia (301371), Meilitiantian Medical Health, and Qingsong Co. (300132) [2]. Industry Overview - Demand remains stable, with the rise of domestic brands in the beauty and personal care sectors accelerating. The cosmetics retail sales for January to April 2025 increased by 4% year-on-year, which is a 0.7 percentage point underperformance compared to the overall retail market, but shows improvement from 2024. The overall demand is stable, with leading domestic brands performing well and the rise of new domestic brands spreading from beauty to personal care categories [3][4]. Trends - The industry is witnessing several trends: 1) Personal care transformation with new products in traditional categories, supported by content e-commerce creating a favorable environment for new product launches [4]. 2) Ingredient innovation, particularly in collagen restructuring, with various types and structural innovations expanding application scenarios [4]. 3) Emotional consumption, where cultural, stylistic, and experiential demands are driving the growth of domestic trends in cosmetics and fragrances [4]. 4) Affordable consumption, where the trend for cost-effectiveness continues under supply-demand resonance, benefiting strong supply chains and well-operated brands [4]. Key Companies - Looking ahead to 2025, the market risk appetite is expected to recover significantly. The beauty sector is characterized by substantial changes and a clear trend of rising domestic brands, indicating strong growth potential and leadership in new consumption [5]. The differentiation among brands is increasing, emphasizing the selection of high-growth targets driven by product innovation and attention to marginal improvements [5].

将投中网设为"星标⭐"，第一时间收获最新推送 消费的热度又拉升了起来。 作者丨 纪佳文 编辑丨 刘燕秋 来源丨 投中网 5 月 28 日，全球投资机构 L Catterton 宣布， 其在最新一轮融资中已筹集约 110 亿美元的资本承诺总额，其中包括超过 67.5 亿美元的旗舰并购策略基金、信贷基金的首关，和成长基金五期、欧洲基金五期、新的日本和中国境内基金的终关等。 投资人涵盖了主权财富基金、养老金、捐赠基金、家办及高净值个人等。 近两年的人民币基金市场上，尽管 KKR 、华平、科勒资本等外资颇为活跃，但贝恩公司最新的私募股权报告显示，人民币 基金占去年亚太地区收购基金募集资金的 43% ，高于 2022 年的 27% ，但仍低于之前五年 59% 的平均份额。 再说消费这个主题，虽说这是个长坡厚雪的赛道，今年又跑出了个"港股三姐妹"，把消费的热度又拉升了起来。不过就我最 近跟投资人和 FA 朋友的交流，因为前两年被"伤得太深"，一些投资机构彻底离场，也可以说是"被出清了"。 在广袤的中国市场上， L Catterton 想必已经蹚出了经验。更重要的，眼下竞争少了，还留在牌桌上的机构反而可以活得更 舒适。因此 ...

Core Viewpoint - The article discusses the controversy surrounding Giant Bio (巨子生物) and its flagship product, Kefu Mei (可复美), which has been accused of potential fraud regarding its collagen content, leading to a crisis of trust among investors and consumers [1][4]. Group 1: Controversy and Market Impact - On May 24, a report from "Dr. Yan's Research Institute" claimed that Kefu Mei's collagen content was undetectable, raising questions about the company's credibility and regulatory compliance [1][4]. - Following the allegations, Giant Bio's stock price fell over 10% on May 26, closing at 73.6 HKD per share, with a total market capitalization of 788.19 billion HKD [4]. - Other companies in the collagen market, such as Jinbo Bio (锦波生物), Marubi (丸美生物), and Furuida (福瑞达), also experienced stock price declines amid the controversy [4]. Group 2: Product and Testing Disputes - The report highlighted three main issues with Kefu Mei: the claimed collagen content was only 0.0177%, below the regulatory threshold of 0.1%, and the absence of glycine, a key amino acid in collagen [9][11]. - Giant Bio defended its product, stating that it complies with national standards and has undergone multiple testing phases to ensure quality [11]. - The lack of standardized testing methods for collagen products in China has been identified as a significant issue, leading to discrepancies in test results from different institutions [12]. Group 3: Industry Context and Growth Potential - The collagen market in China reached 192.4 billion CNY in 2022, with a projected compound annual growth rate of 44.93%, expected to reach 585.7 billion CNY by 2025 [20]. - Companies like Jinbo Bio and Marubi are actively developing their collagen products, with Jinbo Bio reporting a revenue increase of 84.92% in 2024 [20][21]. - The article emphasizes the need for a scientific testing framework and transparent regulatory oversight to address the ongoing challenges in the collagen industry [17][22].

Core Viewpoint - The controversy surrounding Juzhibio's flagship product, Kefu Mei, has raised significant concerns about the authenticity of its collagen claims, leading to a crisis of trust among investors and consumers [1][3][6]. Company Summary - Juzhibio, known as a leader in recombinant collagen, has faced allegations of product falsification, particularly regarding its Kefu Mei product, which reportedly contains only 0.0177% collagen, below the regulatory threshold of 0.1% [3][4]. - The company has stated that all its products are compliant with regulatory standards and have undergone rigorous quality checks [4][6]. - Following the controversy, Juzhibio's stock price fell by 4.04% to HKD 73.6, with a total market capitalization of HKD 788.19 billion as of May 26 [2]. Industry Summary - The demand for aesthetic products, including hyaluronic acid and collagen, has been rising, with major players like Juzhibio and Jinbo Bio seeing growth despite market challenges [2][9]. - The recombinant collagen market in China is projected to grow significantly, reaching CNY 585.7 billion by 2025, with a compound annual growth rate of 44.93% [10][12]. - The lack of standardized testing methods for collagen products has led to discrepancies in product claims and consumer trust issues, highlighting the need for regulatory frameworks in the industry [5][8][12].

Core Insights - The report from Guotai Junan indicates that the basic material needs of residents in China have largely been met, leading to an increased demand for personalized and emotional attributes in products [1][2] - The beauty and personal care sector is highlighted as a representative area for domestic demand growth, with significant structural opportunities due to accelerated product innovation [1][2] Group 1: Demand and Supply Dynamics - On the demand side, China's long-term economic growth has satisfied basic material needs, resulting in a shift towards personalized and emotional product demands [2] - On the supply side, older brands and products are becoming outdated, while Chinese companies are enhancing their capabilities in applying new technologies and cultural aesthetics, leading to accelerated product innovation in beauty and personal care categories [2][3] Group 2: Product Innovation and Market Trends - The report notes that new media channels, such as social media and content e-commerce, have facilitated the rapid dissemination of new products, allowing them to quickly reach target audiences [2] - Specific examples of innovative products include fragrance-based laundry care from Ruoyu Chen, anti-sensitivity toothpaste from Dengkang Oral, and probiotic sanitary pads from Baiya [2] Group 3: Market Share and Growth Potential - The beauty and personal care sector is characterized by strong self-care attributes, high added value, and high profit margins, making brands sensitive to changes in consumer demand [2] - Domestic brands are becoming more agile and efficient in product innovation and channel strategies compared to foreign brands, leading to a continuous increase in market share [2] - According to Euromonitor data, from 2021 to 2024, market shares for various categories such as skincare, makeup, and oral care are projected to increase significantly, with specific increases of 6.1%, 4.9%, 21.6%, 5.7%, and 2.2% respectively [2]

Group 1 - The market experienced a slight adjustment last week, with the brand index closing at 1657.60 points, while several component stocks rose against the trend, including Xinlitai, Tigermed, and Stone Technology [1][2] - Xinlitai led the gains with an increase of 14.96%, followed by Tigermed at 12.48%, and Stone Technology at 11.47%. Other notable gainers included Three Squirrels and Supor, which rose by 7.69% and 6.07% respectively [2] - Since the beginning of 2025, Maimai Biological has seen a significant increase of 51.27%, with Shanghai Jahwa and Xinlitai also showing strong performance with gains of 47.96% and 47.71% respectively [3] Group 2 - Looking ahead, the market is expected to gradually shift towards a more positive trend as investors remain sensitive to favorable factors, with ongoing accumulation of positive elements supporting economic expectations and fundamentals [4] - The current market structure indicates a potential for mid-term positive performance, driven by policy support, domestic technological breakthroughs, and a favorable external environment, which may enhance liquidity in the domestic capital market [4] - In the medium to long term, opportunities may arise in sectors such as domestic demand, technology, and overseas expansion, with a focus on defensive dividend sectors and aggressive technology sectors, including internet and robotics [5]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights a steady recovery in social consumption, with April 2025 retail sales showing a year-on-year increase of 5.1%, and a total retail sales amount of 1618.45 billion yuan for the first four months of 2025, reflecting a 4.7% year-on-year growth [4][25] - The report suggests that the overall social consumption is expected to maintain stable growth due to effective policy measures aimed at boosting domestic demand, with a focus on the high-growth segments of gold jewelry and cosmetics [4][31] Summary by Sections Retail Market Overview - The retail industry index closed at 2110.59 points, down 1.61% for the week, underperforming the Shanghai Composite Index, which fell by 0.57% [6][15] - The jewelry sector showed the highest growth among retail segments, with a weekly increase of 7.56% and a year-to-date increase of 18.83% [17][20] Social Consumption Trends - In April 2025, the retail sales of consumer goods increased by 5.1%, driven by favorable consumption policies and the Qingming holiday effect [28][31] - Online retail sales for the first four months of 2025 reached 4741.9 billion yuan, growing by 7.7%, with physical goods online retail accounting for 24.3% of total retail sales [28][29] Investment Recommendations - Investment focus on high-growth segments under emotional consumption themes, particularly in gold jewelry and cosmetics [7][39] - Recommended companies in the gold jewelry sector include Laopuhuangjin, Chaohongji, and Zhou Dasheng, which are expected to benefit from differentiated product offerings and consumer insights [39][41] - In the cosmetics sector, recommended brands include Proya, Shangmei, and Juzi Biological, which are positioned to capitalize on the ongoing trend of domestic brand growth [39][41] Company Performance Highlights - Proya reported a 28.9% year-on-year increase in net profit for Q1 2025, driven by new product launches [40] - Chaohongji achieved a 25.4% year-on-year revenue growth in Q1 2025, indicating strong brand momentum [40] - Zhou Dasheng's revenue for Q1 2025 was down 47.3% year-on-year, highlighting challenges in the current market environment [40]

Core Viewpoint - The domestic cosmetics and medical beauty industry is experiencing rapid growth driven by policy incentives, recovering consumption, and trade friction, with domestic brands gaining significant market share and attention [1][20]. Group 1: Market Performance - The Wind Cosmetics Index has risen over 20% since April 7, with Proya's stock increasing by more than 20% in the same period, and Marubi's stock rising nearly 70% over three months since February [1]. - During the 618 pre-sale event, over 13,000 brands saw doubled sales, with 43 brands quickly surpassing 100 million yuan in sales, marking a 50% increase in the number of brands in the "billion club" compared to last year [4]. - The beauty industry saw a 6.6% year-on-year increase in total sales during the 2024 618 event, with skincare sales reaching 38.876 billion yuan (up 5.18%) and fragrance and makeup sales at 11.073 billion yuan (up 12.08%) [5]. Group 2: Brand Performance - Domestic brands are outperforming international brands, with Proya's sales on Tmall increasing by 70% year-on-year and Douyin's GMV rising by 110%, significantly exceeding platform growth rates [6]. - International brands like L'Oréal and Estée Lauder have seen a decline in sales, with Lancôme experiencing only slight growth [7]. - The market share of domestic beauty brands reached 50.4% for the first time, surpassing international brands and establishing them as the main force in China's cosmetics market [20]. Group 3: Consumer Trends - There is a growing recognition of domestic brands among consumers, particularly younger consumers who prioritize cost-effectiveness and cultural identity in products, laying a foundation for long-term growth [21]. - The 2024 China Beauty Industry White Paper indicates that over 60% of consumers are willing to purchase domestic beauty products with innovative technology or ingredients [35]. Group 4: Financial Performance - Proya's revenue for 2024 exceeded 10.778 billion yuan, with a net profit growth of 30%, leading to a stock price surge [22]. - Marubi reported a revenue of 2.970 billion yuan for 2024, a year-on-year increase of 33.44%, with a net profit of 342 million yuan, also showing strong growth [25]. - Yatsen Holding, the parent company of Perfect Diary, reported a revenue of 3.393 billion yuan for 2024, a slight decline of 0.63%, and a net loss of 708 million yuan, indicating ongoing financial struggles [30]. Group 5: Competitive Landscape - The beauty industry is becoming increasingly saturated, with brands competing fiercely for market share, leading to a more challenging operating environment for brand owners [18]. - Brands with strong R&D capabilities and comprehensive channel operations are likely to survive, while those lacking core competitiveness may face elimination [39].